Research & KnowledgeEvent: September 1, 2026
Modus Therapeutics Holding AB analyst group published an updated analysis highlighting the ongoing Phase IIa study in CKD with anemia and top-line proof-of-concept data expected around year-end 2026/2027.
Published
Signal category
Research & Knowledge
Quote
“Analyst Group has published an updated analysis of Modus Therapeutics, highlighting the ongoing Phase IIa study in CKD with anemia — with top-line proof-of-concept data expected around year-end 2026/2027”
— Modus Therapeutics Holding AB team
Company
Modus Therapeutics Holding AB
We develop sevuparin to help patients with severe conditions and high unmet medical need.
- Industry
- Biotechnology Research
- Location
- Stockholm, SE
- Company size
- 6 employees
Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical need. The Company’s near-term focus is to develop sevuparin for patients with sepsis/septic shock, a severe and often fatal condition.
Founded 2011